Premium
Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity
Author(s) -
Paulsen Ida F.,
Chakera Annette Hougaard,
Schmidt Grethe,
Drejøe Jennifer,
Klyver Helle,
Oturai Peter S.,
Hesse Birger,
Drzewiecki Krystztof,
Mortensen Jann
Publication year - 2015
Publication title -
clinical physiology and functional imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 67
eISSN - 1475-097X
pISSN - 1475-0961
DOI - 10.1111/cpf.12164
Subject(s) - medicine , perfusion , toxicity , anesthesia , melanoma , leakage (economics) , limb perfusion , nuclear medicine , surgery , hyperthermia , radiology , cancer research , economics , macroeconomics
Summary Introduction The aim is to describe the importance of leakage monitoring in hyperthermic isolated limb perfusion ( ILP ). It is generally recommended that leakage should not exceed 10% because of risk of systemic toxicity. Material and methods Data retrieved by retrospective analysis of 131 perfusions performed in 115 consecutive patients (77 women and 38 men; median age 66 years) with recurrent and/or clinically apparent, cutaneous or subcutaneous melanoma metastases in an extremity. Radionuclide monitoring was performed with continuous, precordial count rate determinations of an intravascular 99m Tc‐labelled tracer infused into the isolated limb circulation. Results One hundred and sixteen of 131 procedures were completed. In 13%, a leakage of ≥10% was detected; in 6% ( n = 8), the cytotoxic drug was never infused because of constant leakage; in 7% ( n = 9), leakage ≥10% was measured during the perfusion resulting in two perfusions being terminated before 30 min, 5 perfusions were considered completed though with early termination (after 30 min, before 60 min), and 2 fully completed. No patients had systemic toxicity requiring treatment, whereas considerable or serious local toxicity were observed in 14%. Three of the patients with leakage ≥10% were successfully treated in a repeated procedure. Conclusion Leakage monitoring using a threshold of 10% during ILP saves the patients from systemic toxicity, however, at the expense of early termination or cancellation of ILP treatment in a few patients and repeated ILP procedures in some.